EUCTR2020-000169-17-BG进行中（未招募）1 期
A Phase 2b Multinational, Randomized, Double-blind, Parallel Group, 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines - ARROYO
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adult participants = 18 years of age
- •2.Physician-confirmed diagnosis of CSU (also known as chronic idiopathic urticaria) for at least 6 months prior to screening (Visit 1).
- •3. Presence of pruritus and wheals for at least 6 consecutive weeks prior to screening (Visit 1), despite receiving standard of care, which may include second generation H1 antihistamines (at approved or up to 4-times approved doses) as monotherapy or in combination with LTRAs and/or H2 blockers.
- •4. Symptomatic during run-in, defined by the following:
- •(a) UAS7 total score of = 16 with an ISS7 of = 8, during the 7 days prior to randomisation (Visit 2)
- •(b) In-clinic UAS total score of = 4 on at least one of the screening days.
- •5. Willing to use a second-generation H1 antihistamine at the approved dose and as monotherapy from the screening visit (Visit 1) until the end of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 130
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. Participants with predominant inducible urticarial
- •2. Participants with diseases, other than chronic urticaria, with urticaria or angioedema symptoms such as urticaria vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema. Additionally, any other skin disease associated with chronic itching and/or skin lesions that, in the investigators opinion, might influence the study evaluations and results (eg, atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.)
- •3. Current malignancy, or history of malignancy, with the exception of:
- •(a) Participants who have had basal cell carcinoma, localised squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided that the participant is in remission and curative therapy was completed at least 12 months prior to the date informed consent, was obtained.
- •(b) Participants who have had other malignancies are eligible provided that the participant is in remission and curative therapy was completed at least 5 years prior to the date informed consent, was obtained.
- •4. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:
- •(a) Affect the safety of the participant throughout the study
- •(b) Influence the findings of the studies or their interpretations
- •(c) Impede the participant’s ability to complete the entire duration of study.
- •5. History of anaphylaxis to any biologic therapy or vaccine.
- •6. A helminth parasitic infection diagnosed within 24 weeks prior to the date informed consent is obtained that has not been treated with, or has failed to respond to standard of care therapy.
- •7. Current active liver disease
- •8. A history of known immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test.
- •9. Use of immunosuppressive medication, including, but not limited to: methotrexate, cyclosporine, azathioprine, topical and systemic corticosteroids within 4 weeks or 5 half-lives prior to the date informed consent is obtained, whichever is longer.
研究者
相似试验
进行中（未招募）
1 期
Study to investigate the use of benralizumab in chronic spontaneous urticariaEUCTR2020-000169-17-DEAstraZeneca AB160
进行中（未招募）
1 期
Study to investigate the use of benralizumab in patients with atopic dermatitisModerate to Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-000285-42-CZAstraZeneca AB160
进行中（未招募）
1 期
Study to investigate the use of benralizumab in patients with atopic dermatitisModerate to Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-000285-42-PLAstraZeneca AB160
进行中（未招募）
1 期
Study to investigate the use of benralizumab in patients with atopic dermatitisEUCTR2020-000285-42-BGAstraZeneca AB160
进行中（未招募）
1 期
Study to investigate the use of benralizumab in patients with atopic dermatitisModerate to Severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2020-000285-42-FRAstraZeneca AB160